# Apogee (AACP) — News

AACP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/aacp/news

## Recent headlines

- [Paragon Labs expands leadership team with former Apogee executives; Velaris Therapeutics acquired by Alunos Therapeutics, Inc.](https://www.ainvest.com/news/paragon-labs-expands-leadership-team-apogee-executives-velaris-therapeutics-acquired-alunos-therapeutics-2610) — AInvest Wire, Oct 13, 2026
- [Apogee Enterprises shares up 19.2% premarket after co raises FY profit, net sales forecasts](https://www.ainvest.com/news/apogee-enterprises-shares-19-2-premarket-raises-fy-profit-net-sales-forecasts-2610) — AInvest Wire, Oct 6, 2026
  Apogee Enterprises Inc. (NASDAQ: APOG) shares surged 19.2% in pre-market trading following the company's announcement of an upward revision to its fiscal year (FY) profit and net sales forecasts. The company now expects FY revenue to range between $1.40 billion and $1.44 billion, up from the…
- [Apog sees FY adj EPS $3 to $3.40, saw $2.70 to $3.25](https://www.ainvest.com/news/apog-sees-fy-eps-3-3-40-2-70-3-25-2610) — AInvest Wire, Oct 6, 2026
  Apogee Enterprises (NASDAQ:APOG) has raised its full-year adjusted earnings per share (EPS) guidance to a range of $3.00 to $3.40, up from its previous estimate of $2.70 to $3.25. This update reflects improved performance in the second quarter of fiscal 2027, where the company reported adjusted EPS…
- [Apogee Enterprises 2Q EPS $1.07 vs. $1.10 y/y](https://www.ainvest.com/news/apogee-enterprises-2q-eps-1-07-1-10-2610) — AInvest Wire, Oct 6, 2026
  Apogee Enterprises (NASDAQ:APOG) reported second-quarter earnings per share (EPS) of $1.07, representing a slight decline from $1.10 in the same period of the previous year . The company generated revenue of $342.7 million, a 1.1% decrease year over year, though it still outperformed analysts'…
- [AbbVie highlights positive results from the phase 2 Apex part B study of Zumilokibart in moderate to severe atopic dermatitis, as a late breaker at EADV 2026](https://www.ainvest.com/news/abbvie-highlights-positive-results-phase-2-apex-part-study-zumilokibart-moderate-severe-atopic-dermatitis-late-breaker-eadv-2026-2609) — AInvest Wire, Sep 30, 2026
  AbbVie has highlighted positive results from the phase 2 APEX part B study of Zumilokibart in patients with moderate-to-severe atopic dermatitis, as a late breaker at the European Academy of Dermatology and Venereology (EADV) 2026 conference. The study demonstrated favorable 16-week induction dose…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).